The objective of this study was to evaluate radiolabeled DOTA-SP90 as a radiotracer for breast cancer. The in vitro competition assay showed that radiolabeled DOTA-SP90 had significant binding affinity to BT-483 cancer cells. Biodistribution, nanoSPECT/CT and nanoPET/CT imaging results indicated that radiolabeled DOTA-SP90 can accumulate in tumors. In addition, radiolabeled DOTA-SP90 peptides can also detect metastatic tumors. Therefore, radiolabeled SP90 peptide may provide the potential capability as diagnostic agent for breast cancer patients.

中文翻译：

---

放射标记的SP90肽在BT-483荷瘤小鼠中的成像和生物分布。

这项研究的目的是评估放射性标记的DOTA-SP90作为乳腺癌的放射性示踪剂。的体外竞争试验表明，放射性标记DOTA-SP90不得不BT-483癌细胞显著结合亲和性。生物分布，nanoSPECT / CT和nanoPET / CT成像结果表明，放射性标记的DOTA-SP90可以在肿瘤中蓄积。此外，放射性标记的DOTA-SP90肽还可以检测转移性肿瘤。因此，放射性标记的SP90肽可能提供作为乳腺癌患者诊断剂的潜在能力。